Forward Health

forwardhealth.co

Forward is a mobile communication platform empowering health and care teams to spend more time with their patients, doing the things that matter. We are a team of doctors and technology experts united by a profound mission: to connect healthcare. Find Forward on your app store today.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

EPIGENTEK LAUNCHED FIRST-OF-ITS-KIND TOOLS TO DETECT SARS-COV-2-TARGETED FURIN ACTIVITY AND SCREEN FOR INHIBITORS AGAINST COVID-19

EpiGentek | July 10, 2020

news image

New York-based biotechnology firm EpiGentek has released a series of SARS-CoV-2 research assays in combatting the ongoing COVID-19 pandemic. The two kits focus on studies of SARS-CoV-2 targeted furin or proprotein convertase (PC) cleavage activity. These first-of-its-kind tools can be used to rapidly detect SARS-CoV-2 targeted PC and facilitated proteases using biological samples as well as screen for inhibitors of these enzymes that cleave SARS-CoV-2 proteins. Subsequent implications can be the...

Read More

Industrial Impact

MOMA THERAPEUTICS ANNOUNCES FIVE-YEAR DISCOVERY COLLABORATION WITH ROCHE FOCUSED ON CRITICAL CANCER DEPENDENCIES

MOMA Therapeutics | January 04, 2024

news image

MOMA Therapeutics, a biotechnology company focused on identifying and targeting highly dynamic, difficult to drug targets in cancer and other diseases, is pleased to announce a strategic collaboration and licensing agreement with Roche. This partnership provides Roche with access to MOMA’s proprietary KnowledgeBase platform for the identification and prosecution of a certain number of novel drug targets involved in promoting cancer cell growth and survival. MOMA’s Kn...

Read More

Medical

AVANTGEN ANNOUNCES LICENSING OF ITS ANTI-SARS-COV-2 ANTIBODY CLONES TO IGM BIOSCIENCES FOR COVID-19 THERAPY DEVELOPMENT

AvantGen | January 12, 2021

news image

AvantGen, Inc., a San Diego-based biotechnology organization with a variety of innovation stages for neutralizer revelation and enhancement, and novel NK and T cell engager age, today reported permitting of a board of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development. Utilizing its novel yeast show framework and huge different human antibody response libraries, AvantGen has distinguished a board of high partiality human monoclonal antibody clo...

Read More

Industry Outlook

SOMALOGIC PARTNERS WITH CITOGEN TO EXPAND AUTHORIZED SITE PROGRAM IN EUROPE

Globenewswire | June 13, 2023

news image

SomaLogic, Inc., a leader in proteomics technology, announced their collaboration with Citogen, the Longwood Group’s customer services and support unit, to establish the company’s first authorized site in Spain. As part of the agreement, Citogen will offer the 7,000-plex SomaScan® Assay and provide SomaScan data to their customers in Southern Europe supporting biological research across an array of disciplines including clinical research, population health studies and nutri...

Read More
news image

EPIGENTEK LAUNCHED FIRST-OF-ITS-KIND TOOLS TO DETECT SARS-COV-2-TARGETED FURIN ACTIVITY AND SCREEN FOR INHIBITORS AGAINST COVID-19

EpiGentek | July 10, 2020

New York-based biotechnology firm EpiGentek has released a series of SARS-CoV-2 research assays in combatting the ongoing COVID-19 pandemic. The two kits focus on studies of SARS-CoV-2 targeted furin or proprotein convertase (PC) cleavage activity. These first-of-its-kind tools can be used to rapidly detect SARS-CoV-2 targeted PC and facilitated proteases using biological samples as well as screen for inhibitors of these enzymes that cleave SARS-CoV-2 proteins. Subsequent implications can be the...

Read More
news image

Industrial Impact

MOMA THERAPEUTICS ANNOUNCES FIVE-YEAR DISCOVERY COLLABORATION WITH ROCHE FOCUSED ON CRITICAL CANCER DEPENDENCIES

MOMA Therapeutics | January 04, 2024

MOMA Therapeutics, a biotechnology company focused on identifying and targeting highly dynamic, difficult to drug targets in cancer and other diseases, is pleased to announce a strategic collaboration and licensing agreement with Roche. This partnership provides Roche with access to MOMA’s proprietary KnowledgeBase platform for the identification and prosecution of a certain number of novel drug targets involved in promoting cancer cell growth and survival. MOMA’s Kn...

Read More
news image

Medical

AVANTGEN ANNOUNCES LICENSING OF ITS ANTI-SARS-COV-2 ANTIBODY CLONES TO IGM BIOSCIENCES FOR COVID-19 THERAPY DEVELOPMENT

AvantGen | January 12, 2021

AvantGen, Inc., a San Diego-based biotechnology organization with a variety of innovation stages for neutralizer revelation and enhancement, and novel NK and T cell engager age, today reported permitting of a board of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development. Utilizing its novel yeast show framework and huge different human antibody response libraries, AvantGen has distinguished a board of high partiality human monoclonal antibody clo...

Read More
news image

Industry Outlook

SOMALOGIC PARTNERS WITH CITOGEN TO EXPAND AUTHORIZED SITE PROGRAM IN EUROPE

Globenewswire | June 13, 2023

SomaLogic, Inc., a leader in proteomics technology, announced their collaboration with Citogen, the Longwood Group’s customer services and support unit, to establish the company’s first authorized site in Spain. As part of the agreement, Citogen will offer the 7,000-plex SomaScan® Assay and provide SomaScan data to their customers in Southern Europe supporting biological research across an array of disciplines including clinical research, population health studies and nutri...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us